WuXi Clinical

WuXi Clinical, a wholly owned subsidiary of WuXi AppTec, is a global Contract Research Organization (CRO) providing a comprehensive range of services in clinical development. We provide Phase I to Phase IV clinical development services & BE (Bioequivalence) , for products including pharmaceuticals, biologics, and medical devices. With expertise spanning all major therapeutic areas, we deliver the unique blend of an experienced team, combined with the creativity, responsiveness, and customer centric-focus of a highly nimble organization. This forward-thinking approach has allowed us to work on a variety of projects ranging from first-in-human products to marketed drugs and devices. WuXi Clinical was formed by the merging of capabilities in ResearchPoint Global – a flexible US headquartered CRO that specializes in global clinical trials for small to mid-sized biopharma customers – and WuXi AppTec. In May 2019, the successful acquisition of Pharmapace, a statistical analysis company based in San Diego, CA further expanded the scale of our offering, and improved the comprehensive capability of our integrated research and development service platform to help innovative partners around the globe develop pharmaceutical products better and faster. Through WuXi AppTec’s robust infrastructure, we are able to customize our services to meet our client’s needs, whether full or functional service is required. We are able to work seamlessly within the WuXi AppTec family and/or with outside vendors to provide central lab, manufacturing, bio-analytical testing, biomarker testing, and site management services thus allowing us to offer a more synergistic, one-stop approach to global clinical development.